Lobelina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lobelina" in Italian language version.

refsWebsite

Global rank Italian rank

4^th place

9^th place

799^th place

22^nd place

2^nd place

7^th place

399^th place

1,563^rd place

1rightdiagnosis.com

low place

low place

doi.org

dx.doi.org

Lobeline for smoking cessation, vol. 2, DOI:10.1002/14651858.CD000124.pub2, PMID 22336780.
«On the basis of the trials which have been published in the past sixty years there is no evidence that lobeline has any long term effect on smoking cessation.»
Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status, vol. 68, 2008, DOI:10.2165/00003495-200868080-00005, PMID 18484799.
Lobelane decreases methamphetamine self-administration in rats, vol. 571, DOI:10.1016/j.ejphar.2007.06.003, PMID 17612524.
Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum, vol. 312, DOI:10.1124/jpet.104.072264, PMID 15331654.
Lobeline augments and inhibits cocaine-induced hyperactivity in rats, vol. 79, DOI:10.1016/j.lfs.2006.05.006, PMID 16765386.
Lobeline, a nicotinic partial agonist attenuates alcohol consumption and preference in male C57BL/6J mice, vol. 97, DOI:10.1016/j.physbeh.2009.02.031, PMID 19268674.
Zheng G, Dwoskin LP, Crooks PA, Vesicular monoamine transporter 2: role as a novel target for drug development, in The AAPS Journal, vol. 8, n. 4, novembre 2006, pp. E682-92, DOI:10.1208/aapsj080478, PMID 17233532.
Zheng F, Zheng G, Deaciuc AG, Zhan CG, Dwoskin LP, Crooks PA, Computational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2, in Bioorganic & Medicinal Chemistry, vol. 15, n. 8, aprile 2007, pp. 2975–92, DOI:10.1016/j.bmc.2007.02.013, PMID 17331733.
Zheng G, Dwoskin LP, Deaciuc AG, Norrholm SD, Crooks PA, Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter, in Journal of Medicinal Chemistry, vol. 48, n. 17, agosto 2005, pp. 5551–60, DOI:10.1021/jm0501228, PMID 16107155.
Wilhelm CJ, Johnson RA, Eshleman AJ, Janowsky A, Lobeline effects on tonic and methamphetamine-induced dopamine release, in Biochemical Pharmacology, vol. 75, n. 6, marzo 2008, pp. 1411–5, DOI:10.1016/j.bcp.2007.11.019, PMID 18191815.
Wilhelm CJ, Johnson RA, Lysko PG, Eshleman AJ, Janowsky A, Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system, in The Journal of Pharmacology and Experimental Therapeutics, vol. 310, n. 3, settembre 2004, pp. 1142–51, DOI:10.1124/jpet.104.067314, PMID 15102929.
Zheng G, Horton DB, Deaciuc AG, Dwoskin LP, Crooks PA, Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters, in Bioorganic & Medicinal Chemistry Letters, vol. 16, n. 19, ottobre 2006, pp. 5018–21, DOI:10.1016/j.bmcl.2006.07.070, PMID 16905316.
Miller DK, Harrod SB, Green TA, Wong MY, Bardo MT, Dwoskin LP, Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats, in Pharmacology, Biochemistry, and Behavior, vol. 74, n. 2, gennaio 2003, pp. 279–86, DOI:10.1016/s0091-3057(02)00996-6, PMID 12479946.
Miller DK, Lever JR, Rodvelt KR, Baskett JA, Will MJ, Kracke GR, Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists, in Drug and Alcohol Dependence, vol. 89, 2–3, luglio 2007, pp. 282–91, DOI:10.1016/j.drugalcdep.2007.02.003, PMID 17368966.
Ma Y, Wink M, Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells, in Phytomedicine, vol. 15, n. 9, settembre 2008, pp. 754–8, DOI:10.1016/j.phymed.2007.11.028, PMID 18222670.
Abdallah HM, Al-Abd AM, El-Dine RS, El-Halawany AM, P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review, in Journal of Advanced Research, vol. 6, n. 1, gennaio 2015, pp. 45–62, DOI:10.1016/j.jare.2014.11.008, PMID 25685543.
Miller DK, Crooks PA, Zheng G, Grinevich VP, Norrholm SD, Dwoskin LP, Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters, in The Journal of Pharmacology and Experimental Therapeutics, vol. 310, n. 3, settembre 2004, pp. 1035–45, DOI:10.1124/jpet.104.068098, PMID 15121762.
Adámková S, Frébort I, Sebela M, Pec P, Probing the active site of pea seedlings amine oxidase with optical antipodes of sedamine alkaloids, in Journal of Enzyme Inhibition, vol. 16, n. 4, ottobre 2001, pp. 367–72, DOI:10.1080/14756360109162385, PMID 11916142.

drugs.com

Lobelia, su drugs.com.

nih.gov

ncbi.nlm.nih.gov

Lobeline for smoking cessation, vol. 2, DOI:10.1002/14651858.CD000124.pub2, PMID 22336780.
«On the basis of the trials which have been published in the past sixty years there is no evidence that lobeline has any long term effect on smoking cessation.»
Smoking cessation, vol. 48, PMID 14651764.
Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status, vol. 68, 2008, DOI:10.2165/00003495-200868080-00005, PMID 18484799.
Lobelane decreases methamphetamine self-administration in rats, vol. 571, DOI:10.1016/j.ejphar.2007.06.003, PMID 17612524.
Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum, vol. 312, DOI:10.1124/jpet.104.072264, PMID 15331654.
Lobeline augments and inhibits cocaine-induced hyperactivity in rats, vol. 79, DOI:10.1016/j.lfs.2006.05.006, PMID 16765386.
Lobeline, a nicotinic partial agonist attenuates alcohol consumption and preference in male C57BL/6J mice, vol. 97, DOI:10.1016/j.physbeh.2009.02.031, PMID 19268674.
Zheng G, Dwoskin LP, Crooks PA, Vesicular monoamine transporter 2: role as a novel target for drug development, in The AAPS Journal, vol. 8, n. 4, novembre 2006, pp. E682-92, DOI:10.1208/aapsj080478, PMID 17233532.
Zheng F, Zheng G, Deaciuc AG, Zhan CG, Dwoskin LP, Crooks PA, Computational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2, in Bioorganic & Medicinal Chemistry, vol. 15, n. 8, aprile 2007, pp. 2975–92, DOI:10.1016/j.bmc.2007.02.013, PMID 17331733.
Zheng G, Dwoskin LP, Deaciuc AG, Norrholm SD, Crooks PA, Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter, in Journal of Medicinal Chemistry, vol. 48, n. 17, agosto 2005, pp. 5551–60, DOI:10.1021/jm0501228, PMID 16107155.
Wilhelm CJ, Johnson RA, Eshleman AJ, Janowsky A, Lobeline effects on tonic and methamphetamine-induced dopamine release, in Biochemical Pharmacology, vol. 75, n. 6, marzo 2008, pp. 1411–5, DOI:10.1016/j.bcp.2007.11.019, PMID 18191815.
Wilhelm CJ, Johnson RA, Lysko PG, Eshleman AJ, Janowsky A, Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system, in The Journal of Pharmacology and Experimental Therapeutics, vol. 310, n. 3, settembre 2004, pp. 1142–51, DOI:10.1124/jpet.104.067314, PMID 15102929.
Zheng G, Horton DB, Deaciuc AG, Dwoskin LP, Crooks PA, Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters, in Bioorganic & Medicinal Chemistry Letters, vol. 16, n. 19, ottobre 2006, pp. 5018–21, DOI:10.1016/j.bmcl.2006.07.070, PMID 16905316.
Damaj MI, Patrick GS, Creasy KR, Martin BR, Pharmacology of lobeline, a nicotinic receptor ligand, in The Journal of Pharmacology and Experimental Therapeutics, vol. 282, n. 1, luglio 1997, pp. 410–9, PMID 9223582.
Miller DK, Harrod SB, Green TA, Wong MY, Bardo MT, Dwoskin LP, Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats, in Pharmacology, Biochemistry, and Behavior, vol. 74, n. 2, gennaio 2003, pp. 279–86, DOI:10.1016/s0091-3057(02)00996-6, PMID 12479946.
Miller DK, Lever JR, Rodvelt KR, Baskett JA, Will MJ, Kracke GR, Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists, in Drug and Alcohol Dependence, vol. 89, 2–3, luglio 2007, pp. 282–91, DOI:10.1016/j.drugalcdep.2007.02.003, PMID 17368966.
Ma Y, Wink M, Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells, in Phytomedicine, vol. 15, n. 9, settembre 2008, pp. 754–8, DOI:10.1016/j.phymed.2007.11.028, PMID 18222670.
Abdallah HM, Al-Abd AM, El-Dine RS, El-Halawany AM, P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review, in Journal of Advanced Research, vol. 6, n. 1, gennaio 2015, pp. 45–62, DOI:10.1016/j.jare.2014.11.008, PMID 25685543.
Miller DK, Crooks PA, Zheng G, Grinevich VP, Norrholm SD, Dwoskin LP, Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters, in The Journal of Pharmacology and Experimental Therapeutics, vol. 310, n. 3, settembre 2004, pp. 1035–45, DOI:10.1124/jpet.104.068098, PMID 15121762.
Adámková S, Frébort I, Sebela M, Pec P, Probing the active site of pea seedlings amine oxidase with optical antipodes of sedamine alkaloids, in Journal of Enzyme Inhibition, vol. 16, n. 4, ottobre 2001, pp. 367–72, DOI:10.1080/14756360109162385, PMID 11916142.

pubchem.ncbi.nlm.nih.gov

(-)-Sedamine, CID=442657, in PubChem Database, National Center for Biotechnology Information. URL consultato il 7 luglio 2019.

oadoi.org

Lobeline for smoking cessation, vol. 2, DOI:10.1002/14651858.CD000124.pub2, PMID 22336780.
«On the basis of the trials which have been published in the past sixty years there is no evidence that lobeline has any long term effect on smoking cessation.»
Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status, vol. 68, 2008, DOI:10.2165/00003495-200868080-00005, PMID 18484799.
Lobelane decreases methamphetamine self-administration in rats, vol. 571, DOI:10.1016/j.ejphar.2007.06.003, PMID 17612524.
Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum, vol. 312, DOI:10.1124/jpet.104.072264, PMID 15331654.
Lobeline augments and inhibits cocaine-induced hyperactivity in rats, vol. 79, DOI:10.1016/j.lfs.2006.05.006, PMID 16765386.
Lobeline, a nicotinic partial agonist attenuates alcohol consumption and preference in male C57BL/6J mice, vol. 97, DOI:10.1016/j.physbeh.2009.02.031, PMID 19268674.
Zheng G, Dwoskin LP, Crooks PA, Vesicular monoamine transporter 2: role as a novel target for drug development, in The AAPS Journal, vol. 8, n. 4, novembre 2006, pp. E682-92, DOI:10.1208/aapsj080478, PMID 17233532.
Zheng F, Zheng G, Deaciuc AG, Zhan CG, Dwoskin LP, Crooks PA, Computational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2, in Bioorganic & Medicinal Chemistry, vol. 15, n. 8, aprile 2007, pp. 2975–92, DOI:10.1016/j.bmc.2007.02.013, PMID 17331733.
Zheng G, Dwoskin LP, Deaciuc AG, Norrholm SD, Crooks PA, Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter, in Journal of Medicinal Chemistry, vol. 48, n. 17, agosto 2005, pp. 5551–60, DOI:10.1021/jm0501228, PMID 16107155.
Wilhelm CJ, Johnson RA, Eshleman AJ, Janowsky A, Lobeline effects on tonic and methamphetamine-induced dopamine release, in Biochemical Pharmacology, vol. 75, n. 6, marzo 2008, pp. 1411–5, DOI:10.1016/j.bcp.2007.11.019, PMID 18191815.
Wilhelm CJ, Johnson RA, Lysko PG, Eshleman AJ, Janowsky A, Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system, in The Journal of Pharmacology and Experimental Therapeutics, vol. 310, n. 3, settembre 2004, pp. 1142–51, DOI:10.1124/jpet.104.067314, PMID 15102929.
Zheng G, Horton DB, Deaciuc AG, Dwoskin LP, Crooks PA, Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters, in Bioorganic & Medicinal Chemistry Letters, vol. 16, n. 19, ottobre 2006, pp. 5018–21, DOI:10.1016/j.bmcl.2006.07.070, PMID 16905316.
Miller DK, Harrod SB, Green TA, Wong MY, Bardo MT, Dwoskin LP, Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats, in Pharmacology, Biochemistry, and Behavior, vol. 74, n. 2, gennaio 2003, pp. 279–86, DOI:10.1016/s0091-3057(02)00996-6, PMID 12479946.
Miller DK, Lever JR, Rodvelt KR, Baskett JA, Will MJ, Kracke GR, Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists, in Drug and Alcohol Dependence, vol. 89, 2–3, luglio 2007, pp. 282–91, DOI:10.1016/j.drugalcdep.2007.02.003, PMID 17368966.
Ma Y, Wink M, Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells, in Phytomedicine, vol. 15, n. 9, settembre 2008, pp. 754–8, DOI:10.1016/j.phymed.2007.11.028, PMID 18222670.
Abdallah HM, Al-Abd AM, El-Dine RS, El-Halawany AM, P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review, in Journal of Advanced Research, vol. 6, n. 1, gennaio 2015, pp. 45–62, DOI:10.1016/j.jare.2014.11.008, PMID 25685543.
Miller DK, Crooks PA, Zheng G, Grinevich VP, Norrholm SD, Dwoskin LP, Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters, in The Journal of Pharmacology and Experimental Therapeutics, vol. 310, n. 3, settembre 2004, pp. 1035–45, DOI:10.1124/jpet.104.068098, PMID 15121762.
Adámková S, Frébort I, Sebela M, Pec P, Probing the active site of pea seedlings amine oxidase with optical antipodes of sedamine alkaloids, in Journal of Enzyme Inhibition, vol. 16, n. 4, ottobre 2001, pp. 367–72, DOI:10.1080/14756360109162385, PMID 11916142.

rightdiagnosis.com

Symptoms of Plant poisoning -- Lobeline, su rightdiagnosis.com.